RLMD Relmada Therapeutics, Inc.
$4.52▲ +11.06%
Healthcare
Other
After hours
$4.57▲ +1.10%
Sep 11, 7:59 PM ET
Volume 2.62M
Avg Volume (10D) 1.18M
Key Metrics & Fundamentals
Market Cap
$482.15M
P/E Ratio
–
Div Yield
–%
52W Range
1.45 - 8.00
% vs 50 MA
-20.78%
% vs 200 MA
-25.68%
RSI-14
28.8
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.77
Free Cash Flow
-$9.61M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$14.81M
COGS
–
Operating Exp
$15.01M
Operating Income
-$15.01M
EBIT
-$15.01M
Pretax Income
-$12.91M
Net Income
-$12.91M
EPS (Diluted)
-0.11
Price & Volume History
Loading chart…
Recent News
Relmada Therapeutics Shares Rise After CEO, CFO Buy 200,000 Shares Each
MT Newswires · Sep 11, 2026 6:30 PM
Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
GlobeNewswire · Sep 1, 2026 12:00 PM
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Zacks · Aug 31, 2026 1:35 PM
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
Zacks · Aug 25, 2026 1:55 PM
Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround
Zacks · Aug 11, 2026 1:35 PM
Relmada Therapeutics Q2 Earnings Call Highlights
MarketBeat · Aug 7, 2026 11:03 AM
Relmada Therapeutics Inc (RLMD) (Q2 2026) Earnings Call Highlights: Strong Phase 2 Data and FDA ...
GuruFocus.com · Aug 7, 2026 5:09 AM
Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 6, 2026 8:05 PM
Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer
GlobeNewswire · Jul 28, 2026 12:30 PM
Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
GlobeNewswire · Jul 16, 2026 11:05 AM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See RLMD's money flow as a full page
Social Sentiment
No Reddit posts found for RLMD.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.